Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Gastrointest Surg ; 10(4): 567-74, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16627223

ABSTRACT

Complicated intra-abdominal infections usually mandate prompt surgical intervention supplemented by appropriate antimicrobial therapy. The aim of this study was to demonstrate that ertapenem was not inferior to piperacillin-tazobactam for the treatment of community-acquired intra-abdominal infections. A randomized open-label active-comparator clinical trial was conducted at 48 medical centers on four continents from December 2001 to February 2003. Adult patients with intra-abdominal infections requiring surgery were randomized to receive either ertapenem 1 g daily or piperacillin/tazobactam 13.5 g daily in 3-4 divided doses. The primary analysis of efficacy was the clinical response rate in clinically and microbiologically evaluable patients at the test-of-cure assessment 2 weeks after completion of therapy. All treated patients were included in the safety analysis. Patient demographics, disease characteristics, and treatment duration in both treatment groups were generally similar. The most commonly isolated pathogens at baseline were E coli (greater than 50% of cases in each group) and B fragilis ( approximately 9%). Favorable clinical response rates were 107/119 (90%) for ertapenem recipients and 107/114 (94%) for piperacillin/tazobactam recipients. The frequencies of drug-related adverse events, most commonly diarrhea and elevated serum alanine aminotransferase levels, were similar in both treatment groups. Six of 180 ertapenem recipients (3%) and two of 190 piperacillin/tazobactam recipients (1%) had serious drug-related adverse experiences. In this study, ertapenem and piperacillin/tazobactam were comparably safe and effective treatments for adult patients with complicated intra-abdominal infections.


Subject(s)
Abdomen/microbiology , Anti-Bacterial Agents/therapeutic use , Bacterial Infections/surgery , beta-Lactams/therapeutic use , Abscess/drug therapy , Abscess/microbiology , Abscess/surgery , Adolescent , Adult , Aged , Aged, 80 and over , Alanine Transaminase/blood , Anti-Bacterial Agents/adverse effects , Bacterial Infections/drug therapy , Bacteroides Infections/drug therapy , Bacteroides Infections/surgery , Bacteroides fragilis , Diarrhea/chemically induced , Ertapenem , Escherichia coli Infections/drug therapy , Escherichia coli Infections/surgery , Female , Gastrointestinal Diseases/drug therapy , Gastrointestinal Diseases/microbiology , Gastrointestinal Diseases/surgery , Humans , Male , Middle Aged , Penicillanic Acid/adverse effects , Penicillanic Acid/analogs & derivatives , Penicillanic Acid/therapeutic use , Peritonitis/drug therapy , Peritonitis/microbiology , Peritonitis/surgery , Piperacillin/adverse effects , Piperacillin/therapeutic use , Piperacillin, Tazobactam Drug Combination , Prospective Studies , Treatment Outcome , beta-Lactams/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...